Afrezza

A Deep Dive Into MannKind's Big Bet On Afrezza

New Label For Afrezza Could Turn Things Around At MannKind

What A Week For MannKind

New Label For Afrezza Could Turn Things Around At MannKind

What A Week For MannKind

MannKind Is 'Making Progress' On Its Alternative To Mylan's EpiPen, Report Says

Why Goldman Is Still Selling Mannkind

MannKind Is 'Making Progress' On Its Alternative To Mylan's EpiPen, Report Says

Why Goldman Is Still Selling Mannkind

MannKind Is Plummeting

Is MannKind Becoming A Penny Stock? Vetr Crowd Isn't Optimistic

Afrezza Recent News

Diabetic Investor On MannKind: 'There's A Reason Why So Many People Are Short This Stock'

Calls Of Note: The Research Moving Stocks Today

MannKind Corporation Sinks: CFO Says 'We're Not There Yet' With Afrezza

Jefferies: MannKind's Consumer Ads For Afrezza May Increase Awareness

MannKind 'Facing Low Profitability And Delayed Profits' As Afrezza Ramp Fizzles, Goldman Says

Piper Jaffray Dishes On MannKind's Afrezza Data

MannKind Disappoints Again With Afrezza Sales

What's Afrezza's Ultimate Potential For MannKind?

Analyst: MannKind Afrezza Estimates Are Being Changed 'Based On Physician Feedback'

Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments

Markets Little Changed As The Quarter Comes To An End

One Small Step For Afrezza, One Huge Step For MannKind?

Market Wrap For April 7: Bears In Complete Control As Markets Get Hammered Yet Again

Market Wrap For April 2: Markets On Four-Day Winning Streak

Market Wrap For March 31: Stocks Rally As Yellen Confirms Support For Economy

Market Wrap For March 28: Markets Still Positive Despite Giving Up Early Gains

MannKind Corporation Down 23.2% After Hitting 52-Week Low (MNKD)

MannKind Corp Climbs 8.6% (MNKD)